Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Pastimes : Let's Talk About Our Feelings!!! -- Ignore unavailable to you. Want to Upgrade?

To: Alan Smithee who wrote (106446)	6/24/2005 2:39:23 AM
From: Grainne	Respond to of 108807

Do you have a citation to disprove my assertion? I didn't think so, or you would have offered it. See the last paragraph particularly from a Johns Hopkins website: 9/15/02 Heart Disease Gene Linked To Prostate Cancer Mutations in a "heart disease gene" have been implicated in hereditary prostate cancer, offering new evidence that at least some cases of prostate cancer may begin with an infection and inflammatory response, the researchers report in the Sept. 16 advance online edition of Nature Genetics. The gene, called macrophage scavenger receptor-1 (MSR1), was identified more than 20 years ago as a factor in plaque formation in arteries. It normally helps immune system cells called macrophages clean up cellular debris from bacterial infections and damaged fats or lipids. The Hopkins investigators suspected that MSR1 mutations might keep macrophages from cleaning up properly after prostate infections, producing inflammatory lesions that are often markers of prostate cancer. As MSR1's first link to cancer, the discovery may tie infections and similar environmental exposures to prostate cancer in a way we haven't thought about before, says William Isaacs, PhD, professor of urology and oncology at the Brady Urological Institute and Kimmel Cancer Center at Johns Hopkins. Overall, the research team found that MSR1 mutations were about seven times more common in men with prostate cancer than in those without. Mutations were found in 12.5 percent of African American men with prostate cancer, versus 1.8 percent without the disease. In men of European descent, MSR1 mutations were present in 4.4 percent of prostate cancer patients and less than one percent of others. More Info Nature Genetics, Advance Online, Sept. 16, 2002 hopkinsmedicine.org